Bioavailability and pharmacokinetic profile of grape pomace phenolic compounds in humans by Castello, Fabio et al.
Contents lists available at ScienceDirect
Archives of Biochemistry and Biophysics
journal homepage: www.elsevier.com/locate/yabbi
Bioavailability and pharmacokinetic proﬁle of grape pomace phenolic
compounds in humans
Fabio Castelloa, Giuseppina Costabileb, Letizia Bresciania, Michele Tassottia, Daniele Naviglioc,
Delia Luongod, Paola Ciciolab, Marilena Vitaleb, Claudia Vetranib, Gianni Galavernaa,
Furio Brighentia, Rosalba Giaccoe, Daniele Del Rioa,f,g,∗, Pedro Menaa
a Department of Food & Drugs, University of Parma, Via Volturno 39, 43125 Parma, Italy
bDepartment of Clinical Medicine and Surgery, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy
c Department of Chemical Sciences, Federico II University of Naples, Via Cintia 21, 80126 Naples, Italy
d CNR-Institute of Biostructures and Bioimaging, Via Tommaso De Amicis, 95, 80131 Naples, Italy
e Institute of Food Science, National Research Council, Via Roma 64, 83100 Avellino, Italy
fDepartment of Veterinary Science, University of Parma, Via Volturno 39, 43125 Parma, Italy
gMicrobiome Research Hub, University of Parma, Parco Area delle Scienze 11/A, 43124 Parma, Italy
A R T I C L E I N F O
Keywords:
Grape pomace
Phenolic metabolite
Bioavailability
Metabolism
Colonic catabolite
Phenyl-γ-valerolactone
A B S T R A C T
Grape pomace, the major byproduct of the wine and juice industry, is a relevant source of bioactive phenolic
compounds. However, polyphenol bioavailability in humans is not well understood, and the inter-individual
variability in the production of phenolic metabolites has not been comprehensively assessed to date. The
pharmacokinetic and excretive proﬁles of phenolic metabolites after the acute administration of a drink made
from red grape pomace was here investigated in ten volunteers. A total of 35 and 28 phenolic metabolites were
quantiﬁed in urine and plasma, respectively. The main circulating metabolites included phenyl-γ-valerolactones,
hydroxybenzoic acids, simple phenols, hydroxyphenylpropionic acids, hydroxycinnamates, and (epi)catechin
phase II conjugates. A high inter-individual variability was shown both in urine and plasma samples, and dif-
ferent patterns of circulating metabolites were unravelled by applying unsupervised multivariate analysis.
Besides the huge variability in the production of microbial metabolites of colonic origin, an important variability
was observed due to phase II conjugates. These results are of interest to further understand the potential health
beneﬁts of phenolic metabolites on individual basis.
1. Introduction
The study of foods containing components with putative beneﬁcial
eﬀects on human health has become a topic of increasing importance
during the last decades. Epidemiological evidence has widely associated
phenolic-rich foods with the prevention of several chronic pathologies,
including cardiovascular diseases, diabetes, and neurodegenerative
diseases, as well as some types of cancer [1–3]. In this framework, the
demand by consumers of foods exerting beneﬁcial eﬀects on human
health leads to the introduction into the global market of new products
rich in phenolic compounds [4,5]. Grape pomace, the major by-product
of wine and grape juice industry, is a rich source of phenolic com-
pounds, including ﬂavonoids (anthocyanins, ﬂavan-3-ols, ﬂavonols,
and ﬂavanones) and non-ﬂavonoids (phenolic acids and their deriva-
tives, stilbenes, and lignans) [6]. The phenolic proﬁle of grape pomace
extracts has been related to antioxidant and anti-inﬂammatory eﬀects,
the prevention of cardiovascular and intestinal diseases, anti-aging and
anti-diabetic properties [7–9].
It should be highlighted that the capability of phenolic compounds
to exert beneﬁcial actions is strictly related to their bioavailability and
the products of their metabolism [1,2,10]. Therefore, the study of the
chemical transformations undergone by phenolic compounds during
their passage through the human organism is a tipping point to properly
understand their biological eﬀects [10,11]. In this sense, several studies
have reported that certain phenolic compounds are highly available,
whereas most of them are scarcely or not absorbed in the small intestine
[12–14]. The vast majority of dietary phenolic compounds reach
therefore the large intestine, where they are further metabolized into
various phenol derivatives by the local gut microbiota [15,16]. The
main phenolic catabolites are formed by the cleavage of ester and
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glycoside bonds, ring-ﬁssion, and chemical modiﬁcations of their more
complex precursors. Once absorbed at colonic level, these newly formed
metabolites may undergo phase I/II transformations exerted by both
gut epithelial cells and hepatocytes. In addition, some phenolic meta-
bolites may undergo an intense enterohepatic recirculation [5,15–18].
Despite the increase in the number of research studies on this subject,
the metabolic fate of phenolic compounds after ingestion in humans
still remains poorly understood. One of the main reasons behind this
lack of knowledge is related to the high inter-individual variability
existing in the bioavailability of these compounds, this being even more
relevant when it comes to colonic catabolites [19]. The absence of
appropriate reference standards is another factor hampering the ade-
quate identiﬁcation and quantiﬁcation of phenolic metabolites in bio-
logical ﬂuids [20].
In the light of the above, we aimed to expand the knowledge on the
metabolic fate of the phenolic compounds contained in a phenolic-rich
drink made from grape pomace. Speciﬁcally, this study was focused on
the analysis, by UHPLC-ESI-MS/MS techniques, of human and/or mi-
crobial phenolic metabolites present in plasma and urine samples of 10
volunteers after the acute administration of a drink prepared with a red
grape pomace extract.
2. Material and methods
2.1. Materials
All chemicals and solvents used in this study were of analytical
grade. Gallic acid, (−)-epicatechin, (+)-catechin, protocatechuic acid,
3-hydroxyphenylpropionic acid, hippuric acid, rutin, and cyanidin-3-O-
glucoside were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Dihydrocaﬀeic acid-3′-sulphate, ferulic acid-4′-sulphate, ferulic acid-4′-
glucuronide, and dihydroferulic acid-4′-sulphate were purchased from
Toronto Research Chemicals (Toronto, ON, Canada). 5-(3′,5′-
Dihydroxyphenyl)-γ-valerolactone, 5-(3′,4′-dihydroxyphenyl)-γ-valer-
olactone, 5-(phenyl)-γ-valerolactone-3′-sulphate, 5-(phenyl)-γ-valer-
olactone-3′-glucuronide, 5-(5′-hydroxyphenyl)-γ-valerolactone-3′-sul-
phate, 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-sulphate, and 5-(5′-
hydroxyphenyl)-γ-valerolactone-3′-glucuronide were synthesized in
house [20,21]. Most of these molecules are catalogued on the standards
sharing platform FoodComEx (www.foodcomex.org). Feruloylglycine
and 4-hydroxyhippuric acid were kindly supplied by Prof. Alan Crozier
(University of California Davis), while hydroxybenzoic acid conjugates
were provided by Dr. Colin Kay (N.C. State University's Plants for
Human Health Institute). All solvents and reagents were purchased
from Sigma (St. Louis, MO, USA), unless otherwise indicated. Ultrapure
water from MilliQ system (Millipore, Bedford, MA, USA) was used
throughout the experiment.
2.2. Clinical design
Ten men, age 26 ± 2 years, BMI 27 ± 3 kg/m2 (mean ± SD)
were recruited through advertising at the Department of Clinical
Medicine and Surgery of the Federico II University, Naples (Table 1).
Inclusion criteria were as follows: age 20–40 years, BMI 20–30 kg/m2,
fasting plasma glucose< 110mg/dL, fasting plasma triglycerides
≤200mg/dL and fasting plasma cholesterol ≤250mg/dL. Exclusion
criteria were: known chronic illness, diabetes, regular intensive phy-
sical activity (deﬁned as more than ﬁve training units/week), renal
failure (serum creatinine>1.7mg/dL), liver disease, anaemia, any
other chronic diseases, use of drugs able to inﬂuence glucose and lipid
metabolism. All participants provided written informed consent, and
the study was approved by the Ethics Committee of the “Federico II”
Naples University. This trial was registered at clinicaltrials.gov as
NCT02865278.
2.3. Study design
Participants were asked to consume a low-polyphenol diet during
the experimental period (3 days before and 2 days after the test day). To
facilitate participant adherence to the dietary restrictions, a list of
permitted and forbidden foods was supplied to the volunteers. On the
day of the test, participants were admitted at the Clinical Research
Center, after 12 h overnight fast for the baseline blood drawing;
thereafter, they consumed 250mL of an aqueous extract drink of red
grape pomace (RGPD; 9.8 g/100mL of soluble carbohydrates and 625
mg/100mL of total polyphenols). Three hours after RGPD consump-
tion, participants consumed a standard low-polyphenol meal, consisting
in white bread (150 g), fatless ham (70 g), spreadable cheese (80 g) and
plumcake (33 g) (903 kcal, 18% protein, 30% fat, 52% carbohydrates).
Plasma samples were collected every hour over 8 h after drink intake.
The next day, a fasting plasma sample was also collected, 24 h after the
test drink. In addition, urine samples were collected at fasting and after
the RGPD consumption at: 0–3, 3–6, 6–10, 10–24, 24–36, and 36–48 h.
The urine volumes were recorded and two aliquots of 2mL each were
stored at −80 °C until analysis.
2.4. Plasma and urine processing
Plasma samples of all volunteers were extracted using a solid phase
extraction (SPE) method previously reported by Feliciano and collea-
gues [22]. Brieﬂy, 350 μL of plasma samples were diluted (1:1) with o-
phosphoric acid 4% (v/v). After plate activation, 600 μL of the diluted
plasma samples were loaded on a 96 well μ-SPE HLB plate (Oasis® HLB
μElution Plate 30 μm, Waters, Milford, Massachusetts, MA, USA).
Samples were then washed with 200 μL of water and with 200 μL of
0.2% (v/v) acetic acid. Finally, samples were eluted with 60 μL of
methanol for UHPLC-ESI-MS/MS analysis.
Urine samples were prepared as previously reported by Brindani
and colleagues [20]. Brieﬂy, urine samples were defrosted, vortexed,
diluted in 0.1% formic acid in water (1:4, v/v), and centrifuged at
12000 rpm for 5min. Finally, urine samples were ﬁltered (0.45 μm
nylon ﬁlter) prior to the UHPLC-ESI-MS/MS analysis.
2.5. UHPLC-ESI-QqQ-MS/MS
Plasma and urine samples were analysed by UHPLC DIONEX
Ultimate 3000 equipped with a TSQ Vantage triple quadrupole mass
spectrometer (QqQ-MS/MS, Thermo Fisher Scientiﬁc Inc., San Jose, CA,
USA) ﬁtted with a heated-electrospray ionization source (H-ESI-II;
Thermo Fisher Scientiﬁc Inc.). Chromatographic and ionization para-
meters for the analysis of the samples were set as previously described
[20]. Metabolite identiﬁcation was carried out by comparing the re-
tention time with authentic standards and/or MS/MS fragmentation
patterns. Up to 160 compounds related mainly to the metabolism of
anthocyanins, ﬂavan-3-ols, ﬂavonols and some phenolic acids, were
monitored in selective reaction monitoring (SRM) mode. Quantiﬁcation
was performed with calibration curves of standards, when available.
When not available, the conjugated metabolites were quantiﬁed with
the most structurally similar compound.
Table 1
Characteristics of participants in the study. Data are expressed as
means ± SD.
Age (years) 26 ± 2
BMI (kg/m2) 27 ± 3
Systolic blood pressure (mm Hg) 122 ± 13
Diastolic blood pressure (mm Hg) 78 ± 8
Fasting plasma glucose (mg/dL) 102 ± 6
Fasting plasma insulin (μU/mL) 10 ± 5
Fasting plasma triglycerides (mg/dL) 85 ± 38
Fasting plasma total cholesterol (mg/dL) 154 ± 31
HDL-cholesterol (mg/dL) 38 ± 5
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2.6. Data analysis and statistics
All data were expressed as mean values ± SEM. PKsolver add-on
program was used to perform pharmacokinetic data analysis in
Microsoft Excel [23]. Multivariate principal component analysis (PCA)
with varimax rotation was applied to explore the inter-individual
variability observed for the plasma proﬁle of phenolic metabolites, by
using SPSS statistics 24.0 software (IBM, Chicago, IL).
3. Results
3.1. Phenolic composition of grape pomace drink
A total of 25 phenolic compounds were identiﬁed and quantiﬁed in
the RGPD. The retention times and spectrometric characteristics of the
compounds detected are reported in Table S1 of the Supplementary
Information. The 250mL of RGPD used in this study contained
3.7 mmol of total phenolic compounds. Anthocyanins were the most
abundant class of phenolic compounds (70%), followed by ﬂavan-3-ol
monomers (23%) and procyanidins (4%). Small amounts of ﬂavonols,
galloyl glucose, and gallic acid were also present in the drink.
3.2. Excretion of phenolic metabolites in urine
Up to 35 phenolic compounds were identiﬁed in urine over 48 h
after ingestion of the RGPD. The UHPLC-ESI-MS/MS parameters ap-
plied to the characterization of these metabolites in urine are reported
in Table S2 of the Supplementary Information. Several classes of phe-
nolic compounds were detected, including simple phenols (catechol
derivatives), hydroxybenzoic acids, hydroxyphenylpropionic acids,
hydroxycinnamic acids, phenyl-valeric acids, phenyl-γ-valerolactones,
and (epi)catechin conjugates (Table 2). A few anthocyanin derivatives
were tentatively detected at trace levels in the 0–3 h urine samples of
only some among the volunteers and, hence, they were not taken into
account. Although a high excretion of hippuric acid and 4′-hydro-
xyhippuric acid was observed, these were not included in the calcula-
tion of the total amount of phenolic compounds since they also origi-
nate from other dietary and endogenous sources [10,16].
Phenyl-γ-valerolactones were the main compounds excreted in
urine, followed by simple phenols and hydroxybenzoic acids, hydro-
xyphenylpropionic and hydroxycinnamic acids and (epi)catechins
(Fig. 1). Basal amounts of phenyl-γ-valerolactones in urine were neg-
ligible as a consequence of the 3-day low-polyphenol diet (Table 2). A
measurable urinary excretion of phenyl-γ-valerolactones was already
observed after 3 h from the consumption of the RGPD, accounting for
the 7.2% of the total excretion of these colonic metabolites. The max-
imum excretion of phenyl-γ-valerolactones was found in the 3–6 h urine
samples (32.5% of the total excretion), followed by a continuous ex-
cretion until the 24–36 h urine sample (Table 2). In all volunteers, the
major contribution to their excretion was from the phase II conjugates
of 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (92.2%), mainly the sul-
phate (compound 30, 56.2%) and glucuronide forms (17 and 19,
33.5%). Instead, 5-hydroxyphenyl-γ-valerolactone derivatives con-
tributed to the 6.7% of the total excretion of phenyl-γ-valerolactones
(compounds 25 and 35) and, contrary to dihydroxyphenyl-γ-valer-
olactones, their excretion peaked in the 10–24 urine sample (Table 2).
The 9 simple phenols and hydroxybenzoic acids detected in urine
samples had a total 0–48 h excretion of 202.0 ± 13.6 μmol (Table 2).
The maximum excretion of these metabolites was reached after 6 h from
the ingestion of RGPD, like for phenyl-γ-valerolactones. Simple phenols
and hydroxybenzoic acids also showed an additional peak after 36 h
following RGPD consumption (Fig. 1). Methylpyrogallol-sulphate (7),
benzoic acid-4-sulphate (10), and the glucuronide and sulphate forms
of vanillic acid (2 and 13, respectively) were the main simple phenols
and hydroxybenzoic acids excreted in urine (Table 2).
A total of 7 hydroxyphenylpropionic acids and hydroxycinnamic
acids were identiﬁed in urine (Table 2). The total 0–48 h excretion of
these metabolites was 38.7 ± 1.8 μmol, much lower than for phenyl-γ-
valerolactones and simple phenols and hydroxybenzoic acids. The ur-
inary excretion of hydroxyphenylpropionic and hydroxycinnamic acids
was almost constant along the 48 h, with a small excretion peak re-
corded for the 3–6 h urine samples.
Finally, a total of 6 phase II (epi)catechin metabolites were detected
in urine (Table 2), with a total excretion equal to 9.6 ± 1.7 μmol. In
contrast to the other phenolic classes, these ﬂavan-3-ol metabolites
were excreted more rapidly, reaching a maximum excretion rate in the
ﬁrst 3 h (0–3 h urine samples). The excreted amount decreased drasti-
cally after 6 h from the intake of the RGPD (Table 2).
3.3. Plasma pharmacokinetics
Up to 28 compounds were identiﬁed in the plasma samples collected
from the volunteers following RGPD consumption (details on their
identiﬁcation are presented in Table S2, Supplementary Information).
Maximum plasma concentration (Cmax), time to reach Cmax (tmax), area
under the plasma concentration-time curve (AUC0-24) and half-life of
elimination (t1/2) were calculated for each compound (Table 3). The
pharmacokinetic proﬁles of the main groups of phenolic metabolites
identiﬁed in plasma are illustrated in Fig. 2. Circulating anthocyanins
were not detected. The relative contribution of all the classes of phe-
nolic metabolites detected in plasma to the pool of circulating meta-
bolites is presented in Fig. 3.
Phenyl-γ-valerolactones were the most abundant class of phenolic
metabolites in circulation. As in the case of the urinary samples, the
glucuronide- and sulphate-conjugated isomers of 5-(3′,4′-dihydrox-
yphenyl)-γ-valerolactone (17, 19, and 30) represented the most abun-
dant compounds, with mean Cmax ranging from 268 to 1171 nM. The
rest of the phenyl-γ-valerolactones showed a Cmax that never exceeded
100 nM. Phenyl-γ-valerolactones were not detectable during the ﬁrst
2 h after RGPD intake, but started to peak after 4 h (Fig. 2). Tmax for
dihydroxyphenyl-γ-valerolactone derivatives was about 5–7 h, while it
was 9–11 h for the monohydroxyphenyl-γ-valerolactone conjugates
(Table 3). Their amount decreased progressively 8 h after RGPD con-
sumption, reaching concentration values < 100 nM for all the phenyl-
γ-valerolactones after 24 h from the drink intake. Nevertheless, a high
inter-individual variability was observed and a subject was char-
acterised by values close to 1 μM for the 5-(hydroxyphenyl)-γ-valer-
olactone-sulphate isomers (30) at 24 h.
A total of 10 hydroxybenzoic acids and simple phenols were de-
tected in plasma, being methylpyrogallol-sulphate (7) and proto-
catechuic acid-3-sulphate (9) the most representative compounds.
These two compounds were detected at high concentrations in plasma,
reaching high nM levels (Cmax values of 512.4 ± 117.5 and
408.5 ± 68.7 nM, respectively). Hydroxybenzoic acids identiﬁed in-
cluded protocatechuic acid-3-glucuronide (3), which was not detected
in urine samples. The maximum Cmax of hydroxybenzoic acids and
simple phenols varied signiﬁcantly among metabolites (Table 3). For
instance, Cmax peak for gallic acid (1), protocatechuic acid derivatives
(3, 4, and 9), benzoic acid-sulphate (10), and methylcatechol-sulphate
(8) were observed during the ﬁrst few hours after RGPD intake, with
tmax ranging from 2 to 3 h. On the contrary, vanillic acid derivatives (2
and 13) and methylpyrogallol-sulphate (7) had tmax between 4 and 6 h,
with catechol-sulphate (6) peaking at 11.2 h (Table 3). Moreover, some
compounds peaking during the ﬁrst few hours (1, 3, 4, 9, and 10)
showed a second concentration peak around 6–8 h (data not shown).
The clearance of these compounds was relatively slow, since their levels
remained constant in plasma within the ﬁrst 8 h. Then, for all volun-
teers, plasma concentrations went below 100 nM for all the metabolites
at time 24 h after RGPD intake.
Regarding hydroxyphenylpropionic acids and hydroxycinnamic
acids, up to 5 compounds were identiﬁed in plasma (Table 3). In con-
trast to urine samples, sinapic acid-sulphate (33) and
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hydroxyphenylpropionic acid-sulphate (14) were not detected in
plasma. Ferulic acid-4-glucuronide (12) was the most abundant com-
pound, followed by another phase II conjugate of ferulic acid, fer-
uloylglycine (24). Most of these compounds had a tmax at 5–9 h
(Table 3), although both ferulic acid-4-glucuronide (12) and ferulic
acid-4-sulphate (29) presented a ﬁrst peak at 1 h.
A total of 5 (epi)catechin derivatives were detected in plasma
(Table 3). One of the two methyl(epi)catechin-sulphate isomers de-
tected in urine was not detected in plasma. The Cmax of (epi)catechin
conjugates in plasma were around 100 nM, peaking during the ﬁrst
hours after RGPD intake.
Last, 4′-hydroxyhippuric acid (5) was found in all samples from all
Fig. 1. Total 0–48 h excretion of phenolic metabolites after RGPD consumption:
phenyl-γ-valerolactones (VL, including the phenyl-valeric acid-sulphate-glu-
curonide, dark cyan line), simple phenols and hydroxybenzoic acids (HB, green
line), hydroxyphenylpropionic acids and hydroxycinnamic acids (HPP, red
line), and (epi)catechins (CAT, orange line). The black line corresponds to the
total phenolic metabolites (hippuric acid derivatives were not included).
N=10 except for the last 2 time points where n= 9 (subject #3 was excluded
from these calculations because of a lack of compliance with the study protocol
during the period 24–48 h). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the Web version of this article.)
Table 3
Pharmacokinetic parameters of phenolic metabolites detected in plasma (mean ± SEM, n= 10).
Id.# Phenolic compounds Cmax (nM) Tmax (h) t1/2 (h) AUC0-24 (nmol h L−1)
Simple phenols and hydroxybenzoic acids
1 Gallic acid 124.3 ± 31.9 3.8 ± 0.7 20.5 ± 9.4 607.2 ± 211.3
2 Vanillic acid-4-glucuronide 61.3 ± 9.0 5.7 ± 0.4 6.2 ± 1.4 410.9 ± 82.2
4 Protocatechuic acid 5.9 ± 1.2 4.1 ± 0.8 40.4 ± 13.7 40.9 ± 7.5
3 Protocatechuic acid-3-glucuronide 3.1 ± 0.6 3.0 ± 0.8 6.7 ± 2.3 20.5 ± 3.8
9 Protocatechuic acid-3-sulphate 408.5 ± 68.7 2.1 ± 0.3 3.8 ± 0.4 1088.6 ± 126.3
10 Benzoic acid-4-sulphate 56.7 ± 9.4 3.0 ± 0.7 37.2 ± 14.6 521.3 ± 76.3
13 Vanillic acid-4-sulphate 117.0 ± 30.2 4.0 ± 0.5 4.8 ± 0.6 381.9 ± 121.7
6 Catechol-sulphate 2.9 ± 1.0 11.2 ± 2.9 6.3 ± 1.2 20.8 ± 7.5
7 Methylpyrogallol-sulphate 512.4 ± 117.5 5.9 ± 0.5 3.6 ± 0.5 2724.2 ± 584.2
8 Methylcatechol-sulphate 47.1 ± 7.6 2.4 ± 0.5 3.3 ± 0.6 184.6 ± 23.6
5 4-Hydroxyhippuric acid 98.7 ± 15.1 4.6 ± 0.5 14.8 ± 4.2 874.0 ± 173.4
Hydroxyphenylpropionic and hydroxycinnamic acids
12 Ferulic acid 4-glucuronide 72.8 ± 19.9 7.0 ± 2.0 5.7 ± 1.4 567.5 ± 208.1
24 Feruloylglycine 26.0 ± 3.9 9.3 ± 3.3 26.3 ± 4.9 175.1 ± 28.0
23 Dihydrocaﬀeic acid-sulphate 8.3 ± 1.5 7.0 ± 2.0 40.1 ± 17.0 50.8 ± 19.9
26 Dihydroferulic acid-sulphate 7.7 ± 1.3 8.5 ± 2.7 17.5 ± 6.8 56.4 ± 16.9
28 Ferulic acid-4-sulphate 10.0 ± 1.8 5.2 ± 0.6 17.9 ± 7.0 63.4 ± 16.2
(Epi)catechin derivatives
11 (Epi)catechin-glucuronide-sulphate 6.8 ± 1.5 4.8 ± 0.6 0.9 ± 0.3 20.0 ± 4.5
20 (Epi)catechin-glucuronide 135.5 ± 14.2 1.7 ± 0.3 2.3 ± 0.4 459.9 ± 44.5
27 (Epi)catechin-sulphate, isomer 1 87.0 ± 22.8 1.6 ± 0.2 1.9 ± 0.4 166.2 ± 31.1
29 (Epi)catechin-sulphate, isomer 2 94.9 ± 22.8 2.5 ± 0.5 2.9 ± 0.5 290.2 ± 50.1
32 Methyl(epi)catechin-sulphate, isomer 1 12.6 ± 1.9 2.7 ± 0.8 8.1 ± 1.3 53.1 ± 10.2
Phenyl-γ-valerolactones and phenyl-valeric acids
31 5-Phenyl-valeric acid-sulphate-glucuronide 11.0 ± 1.1 7.9 ± 2.0 36.0 ± 14.1 106.2 ± 29.1
17 5-(3′-Hydroxyphenyl)-γ-valerolactone-4′-glucuronide 268.4 ± 68.2 5.3 ± 0.6 2.1 ± 0.5 1098.2 ± 219.2
19 5-(4′-Hydroxyphenyl)-γ-valerolactone-3′-glucuronide 1171.2 ± 242.7 5.2 ± 0.6 12.4 ± 8.3 6224.8 ± 1175.4
30 5-(Hydroxyphenyl)-γ-valerolactone-sulphate isomers 893.7 ± 201.3 6.3 ± 2.0 4.8 ± 1.1 5196.3 ± 1457.9
25 5-Phenyl-γ-valerolactone-3′-glucuronide 88.4 ± 44.7 9.1 ± 2.5 11.0 ± 2.7 617.0 ± 178.2
35 5-Phenyl-γ-valerolactone-3′-sulphate 69.2 ± 25.2 11.0 ± 2.9 8.1 ± 1.9 441.0 ± 135.7
21 5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone 14.3 ± 3.2 7.0 ± 2.0 39.5 ± 26.4 66.1 ± 16.5
Fig. 2. Metabolites detected in plasma: phenyl-γ-valerolactones (VL, including
the phenyl-valeric acid-sulphate-glucuronide, dark cyan line), simple phenols
and hydroxybenzoic acids (HB, green line), hydroxyphenylpropionic acids and
hydroxycinnamic acids (HPP, red line), and (epi)catechins (CAT, orange line).
Black line corresponds to the total phenolic metabolites excluding 4-hydro-
xyhippuric acid. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article.)
Fig. 3. A) Relative plasma AUC0-24 calculated for phenolic metabolites by class
after RGPD consumption. B) 48 h-excretion in urine of phenolic metabolites.
Phenyl-γ-valerolactones (VL, including phenyl-valeric acid-sulphate-glucur-
onide), simple phenols and hydroxybenzoic acids (HB), hydro-
xyphenylpropionic acids and hydroxycinnamic acids (HPP), and (epi)catechins
(CAT). Hippuric acid derivatives were not included.
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volunteers (Table 3). Although some subjects showed a clear pharma-
cokinetic proﬁle, other subjects did not shown a trend associated with
the intake and metabolism of phenolic compounds.
The relative contribution of the individual classes of phenolic me-
tabolites detected in plasma to the pool of circulating metabolites is
shown in Fig. 3A and it was quite similar to that registered for urine
(Fig. 3B).
3.4. Inter-individual variability in the production and excretion of phenolic
metabolites
A high inter-individual variability was observed in the urinary ex-
cretion of phenolic metabolites, as indicated by the high coeﬃcients of
variation (CV) registered (Table 2). The CV% for each metabolite
ranged from 20 to 167%, with a mean CV of 52%. Total phenolic
compounds urinary excretion varied between 348 and 844 μmol
(Fig. 4A), the CV being 27% (Table 2). This inter-individual variability
in the urinary excretion was also observed among classes of phenolic
compounds (Fig. 4A), and entailed notable diﬀerences in the qualitative
urinary proﬁle of each volunteer, mainly linked to variations in phenyl-
γ-valerolactones, hydroxybenzoic acids and simple phenols. (Fig. 4B).
The proﬁle of plasma circulating metabolites after RGPD intake also
showed an important inter-subject variability. An unsupervised multi-
variate analysis (PCA) of the plasmatic concentrations for each meta-
bolite and individual sample revealed the existence of diﬀerent patterns
among volunteers (Fig. 5). Three principal components (PCs) explained
up to 44.3% of the total variance (Fig. 5A and B). The ﬁrst PC (PC1)
accounted for the 20.1% of the total variability and it was positively
loaded mainly by metabolites peaking in plasma at 4–7 h, such as
phenyl-γ-valerolactones (17, 19, 21, 25, 30, and 35) and vanillic acid
derivatives (2 and 13). PC2, representing the 14.9% of the variance,
was positively linked to compounds achieving maximum plasma con-
centrations during the ﬁrst hours after RGPD intake, like (epi)catechin
conjugates (20, 27, 29, and 32), protocatechuic acid-3-sulphate (9),
and methylcatechol-sulphate (8). PC3 (9.3% of total variance) had
positive loadings for 4-hydroxyhippuric acid (5), dihydrocaﬀeic acid-
sulphate (23) and dihydroferulic acid-sulphate (26), and was correlated
negatively for catechol-sulphate (6).
Plasma sample scores for each PC conﬁrmed the pharmacokinetic
proﬁles previously described, with the samples at collection times 1 and
2 h presenting positive PC2 values and the samples at time points 3–7 h
having positive PC1 scores (Fig. 5C). This accounted for the increases in
the production of epicatechin derivatives during the ﬁrst hours after
RGPD intake and the subsequent production of phenyl-γ-valerolactones
and vanillic acid derivatives. Interestingly, the shift of the diﬀerent time
points for each subject on the plot, and the area covered by the surface
delimited by these points, was quite diﬀerent among subjects. For in-
stance, while volunteer #05 showed PC1 scores close to 0 and max-
imum PC2 scores about 1, volunteer #10 showed PC1 scores close to 6
and PC2 scores by 4 (Fig. 5C and Supplementary Fig. 1A). This fact
demonstrates, through a comprehensive approach, the inter-individual
variability existing on the pharmacokinetic proﬁle of phenolic meta-
bolites from RGPD. Lastly, scores for PC3 (Fig. 5D) also indicated inter-
subject diﬀerences in the pharmacokinetic proﬁles. In this sense, vo-
lunteers #04, #05, and #10 had negative scores for PC3 at times 1–8 h,
while #06 and #09 showed positive scores (Fig. 5D and Supplementary
Fig. 1B). This may account for individual diﬀerences in the production
of catechol-sulphate and dihydrocaﬀeic/dihydroferulic acid sulphates.
4. Discussion
Grape pomace, the major byproduct of the wine and juice industry,
is a relevant source of bioactive phenolic compounds [7,24–27].
However, the human bioavailability of its phenolic compounds is re-
latively unknown, precluding an adequate understanding of the phe-
nolic metabolites behind the putative protective eﬀects of grape po-
mace against several chronic diseases [7,24–28]. Although the work
conducted by Sasot et al. [28] provided great insights in the metabolism
of grape pomace phenolics, the quantiﬁcation of the identiﬁed phenolic
metabolites and the assessment of the inter-individual variability in
their production were not carried out. In the present work, most of the
phenolic metabolites formed in vivo after the consumption of a phe-
nolic-rich RGPD were quantiﬁed using reliable analytical standards, a
key step to further carry out proper in vitro studies on grape pomace
bioactives [20]. This is of particular interest for the unambiguous
identiﬁcation and absolute quantiﬁcation of phenyl-γ-valerolactones,
for which reference standards have only recently become available
[20,21].
Data showed that phenolic metabolites increased in plasma up to
three diﬀerent times, at ∼2 h, 4 h and 6 h after RGPD intake, with
diﬀerent classes of phenolic metabolites peaking at diﬀerent time points
(Fig. 2, Table 3). In urine, maximum phenolic concentration was found
at the collection interval 3–6 h (Table 1), which was in line with the
appearance of metabolites in plasma samples. Moreover, most of the
phenolic compounds underwent an intense phase II metabolism, likely
at the intestinal epithelium level and/or in the liver [18,20,29,30],
being the sulphate-conjugates predominant over the glucuronides.
These results are in agreement with previous reports assessing the
bioavailability of diﬀerent classes of phenolic compounds consumed
simultaneously, like it happens for grape products [5,28,31,32].
Peak plasma concentrations of several hydroxybenzoic acid deri-
vatives occurred approximately at 2- and 4 h after the RGPD supple-
mentation, suggesting absorption in the ﬁrst part of the gastrointestinal
tract and in the small intestine, respectively. Only catechol sulphate
peaked later, which may suggest that it was formed in the large intes-
tine after an intense microbial metabolism of other phenolic scaﬀolds
[1,2]. The biphasic pharmacokinetic proﬁle of some compounds such as
gallic and protocatechuic acid derivatives may occur as result of the
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metabolism of diﬀerent phenolic structures at multiple tissue level,
including the upper and lower parts of the gastrointestinal tract [1,2]. A
recent study on the human bioavailability and metabolism of phenolic
extracts prepared from grape pomace has underlined that both gallic
and protocatechuic acids can be generated from the cleavage of various
anthocyanins [30], from the metabolism of syringic acid [33], and also
from the gallic acid already present in the fed matrix [34,35]. Similarly,
the presence in plasma of ferulic acid, dihydroferulic acid, and dihy-
drocaﬀeic acid conjugates followed kinetics in line with what pre-
viously reported [5,36].
Grape pomace has been reported to be an important source of bioa-
vailable ﬂavan-3-ol monomers [24]. In this study, the absorption proﬁle
of (epi)catechin conjugates showed maximum plasma concentrations
around 1–2 h, with t1/2 of ∼1–3 h, in accordance with previous reports
[5,32,36]. With the exception of a methyl(epi)catechin sulphate isomer,
(epi)catechin derivatives were rapidly cleared from plasma, just a few
hours after RGPD intake, being eliminated in urine during the ﬁrst 6 h.
Moreover, these metabolites only accounted for the 2% of the total
phenolic compounds excreted in urine. On the contrary, their main ring
ﬁssion metabolites of microbial origin, phenyl-γ-valerolactones and
phenyl-valeric acids, had longer t1/2 and resulted to be the most re-
presentative compounds among the phenolic metabolites identiﬁed in
plasma and urine samples. Phenyl-γ-valerolactones peaked after 4–10 h
from the RGPD intake, in good agreement with a recent study, by
Bresciani et al., where three phenyl-γ-valerolactones [5-(phenyl)-
valerolactone-3′-sulphate, 5-(4′-hydroxyphenyl)-valerolactone-3′-sulphate
and 5-(4′-hydroxyphenyl)-valerolactone-3′-glucuronide] were shown
peaking between 5 and 10 h [5]. Moreover, a previous work on the me-
tabolism of green tea ﬂavan-3-ols in humans reported high concentrations
of phenyl-γ-valerolactones in plasma 12 h after tea ingestion [29,37]. This
late appearance of phenyl-γ-valerolactones as a result of ﬂavan-3-ol de-
gradation by the gut microbiota has also been observed in other studies on
diﬀerent food matrices [38–41] or after the intake of radiolabelled epi-
catechin [18]. Regarding the urinary excretion of phenyl-γ-valerolactones,
this went on up to 36 h, in line with a sustained production and absorption
of these metabolites (and/or enterohepatic recirculation) before their
complete elimination in urine [1,42]. Thus, opposite to the other phenolic
metabolites discussed above, phenyl-γ-valerolactones exhibit high con-
centrations for prolonged periods of time after consumption of plant foods
rich in ﬂavan-3-ols. This aspect, also highlighted previously [14,18],
points at these ring ﬁssion colonic metabolites as good candidates to fur-
ther explore the health beneﬁts attributed to the consumption of catechin
and proanthocyanidin food sources [3,43].
The high inter-individual variability in the absorption and excretion
of phenolic derivatives observed in plasma and urine samples is a key
point to be considered, as highlighted in other studies on phenolic
compounds bioavailability [11,19,35,44]. It is now more than clear that
the gut microbiota plays an important role in the inter-individual
variability existing in the biochemical transformations of several phe-
nolic compounds. For instance, a recent study on the in vitro
Fig. 5. Principal component analysis highlighting inter-individual diﬀerences associated with the pharmacokinetic proﬁle of phenolic metabolites. A) Loading plots
of PC1 versus PC2 and B) PC1 versus PC3; C) score plots of the plasma circulating phenolic metabolites for all the volunteers at all the time points (0–24 h) obtained
from PC1 and PC2, and D) from PC1 and PC3. Mn indicates the metabolite number, as reported in Table 3. In the score plots, the number accounts for the collection
time (0, 1, 2, 3, 4, 5, 6, 7, 8, and 24). Details on individual trends are highlighted in Supplementary Fig. 1.
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gastrointestinal digestion of grape pomace extracts has demonstrated
that certain phenolic extracts can promote the growth of speciﬁc
components of the intestinal microbiota and shift bacteria proportions
[45]. Nevertheless, variability due to phase II metabolism, therefore
linked to human enzyme expression and activity, should not be ruled
out, since a part of the variability observed in the present study was
associated with plasma levels of (epi)catechin derivatives.
5. Conclusions
This work on the absorption, metabolism and excretion of red grape
pomace phenolic compounds in humans highlighted a very high
number of phenolic metabolites appearing in circulation and following
diﬀerent pharmacokinetic proﬁles after the intake of RGPD. Some of
these compounds were excreted in urine up to 48 h after intake. Phenyl-
γ-valerolactones were the most relevant and abundant circulating me-
tabolites, followed by some hydroxybenzoic acids and by simple phe-
nols, (epi)catechin conjugates and hydroxyphenylpropionic acids. A
high inter-individual variability was registered, and diﬀerent proﬁles of
plasma circulating metabolites were unravelled. These results high-
lighted diﬀerences not only in the production of gut microbial-derived
metabolites, but involved also the phase II metabolic step, which is
purely mammalian. Regardless of the individual diﬀerences, it can ea-
sily be concluded that the intake of a drink prepared from red grape
pomace can deliver signiﬁcant amounts of diﬀerent phenolic metabo-
lites to the human system. Future investigations should focus both on
the causes behind the observed inter-individual variability and how
these diﬀerences may impact on the putative health properties of this
drink.
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